Clearside Biomedical Opens Enrollment In ODYSSEY Phase 2b Clinical Trial Of CLS-AX In Wet AMD
Portfolio Pulse from Benzinga Newsdesk
Clearside Biomedical has opened enrollment for its ODYSSEY Phase 2b clinical trial of CLS-AX in Wet AMD. The trial is a randomized, double-masked, parallel-group, active-controlled, multi-center study with a duration of 36 weeks.
June 01, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical has started enrollment for its ODYSSEY Phase 2b clinical trial of CLS-AX in Wet AMD, potentially leading to positive results and increased investor interest.
The initiation of the ODYSSEY Phase 2b clinical trial for CLS-AX in Wet AMD is a significant milestone for Clearside Biomedical. Positive results from the trial could lead to increased investor interest and a potential rise in the stock price. The trial's progress should be closely monitored by investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100